Compared with IR-treated only CD133+, the tumorigenic properties of migration/invasion (Figure 7B) and tumor colony formation (Figure 7C) were significantly inhibited in CD133+ treated with DBH alone or DBH combined with BCL-2 siRNA. The gene discussed is BCL2; the disease is neoplasm.